Earnings Snapshot: Zydus Lifesciences, United Spirits, Solar Industries, Max Healthcare, NHPC and Dixon Technologies
- Share.Market
- 7 min read
- Published at : 21 May 2025 02:20 PM
- Modified at : 21 May 2025 02:20 PM
ZYDUSLIFEQ4FY25
Revenue ₹6,528 crores 🔼 18%
PAT ₹1,171 crores 🔻 1%
FY25
Revenue ₹23,242 crores 🔼 19%
PAT ₹4,526 crores 🔼 17%
Zydus Lifesciences concluded FY25 on a strong note, with revenue from operations rising 19% for the full year. In Q4FY25, revenues grew 18% YoY, with India operations accounting for 39% of consolidated revenues. The US formulations segment, contributing 50% to Q4 consolidated revenue, reported a 24% YoY growth. Five new products were launched during the quarter, with 3 ANDA filings and 6 approvals. International formulations also posted an 11.8% YoY growth, backed by broad-based demand across geographies.
Overall, the company credited its growth to a combination of product portfolio strength, sustained R&D investments (₹18,555 crore in FY25), and strategic initiatives aimed at innovation, global expansion, and portfolio diversification.
The board has recommended a final dividend of ₹11 per equity share, subject to shareholder approval. The record date for the same is Friday, July 25, 2025.
Over the last three years, Zydus has given multibagger returns of more than 150%.
UNITDSPRQ4FY25
Net Sales Value ₹3,031 crores 🔼 8.9%
PAT ₹421 crores 🔼 15%
FY25
Net Sales Value ₹12,069 crores 🔼 6.6%
PAT ₹1,582 crores 🔼 12.4%
United Spirits delivered a resilient performance in FY25 despite a challenging consumer environment.
The Prestige & Above (P&A) segment, which contributed nearly 88% of sales, grew 13.2% in Q4 and 9.9% for the full year, reflecting strong consumer preference for premium products. The Popular segment grew modestly by 1.1% in Q4 and 0.8% in FY25. The company also benefitted from the re-entry into the Andhra Pradesh market, which contributed to volume growth.
The board recommended a final dividend of ₹8 per share for FY25, subject to shareholder approval.
SOLARINDSQ4FY25
Net Revenue ₹2,167 crores 🔼 35%
PAT ₹346 crores 🔼 42%
FY25
Net Sales Value ₹7,540 crores 🔼 24%
PAT ₹1,288 crores 🔼 47%
Solar Industries delivered a strong performance in FY25, supported by robust demand across domestic and international markets. The company closed FY25 with its highest-ever order book. As of March 31, 2025, the company’s consolidated order book stood at ₹4,907 crore, out of which ₹3,901 crore was from the defense segment alone, reflecting a sharp uptick in government procurement and exports. A major highlight for the year was the receipt of a landmark order from the Ministry of Defence for the supply of Loitering Munitions (LM-0 and LM-1 variants), demonstrating the company’s growing credibility in the indigenous weapon systems space.
The company successfully commissioned a state-of-the-art propellant plant for Pinaka rockets, making it one of the few private Indian firms capable of end-to-end rocket system integration. On the international front, exports grew significantly, and the company added new geographies for both industrial explosives and defense offerings.
The board recommended a final dividend of ₹10 per equity share, subject to shareholder approval.
Over the last three years, this stock has given multibagger returns of more than 400%.
MAXHEALTHQ4FY25
Revenue ₹2,326 crores 🔼 29%
PAT ₹376 crores 🔼 21%
FY25
Revenue ₹9,065 crores 🔼 26%
PAT ₹1,392 crores 🔼 9%
Max Healthcare Institute continued to expand its network and strengthen its clinical leadership in FY25. Operationally, Max reported its 18th consecutive quarter of growth in revenue and EBITDA. It acquired full ownership of Jaypee Healthcare Ltd, adding a 500-bed hospital in Noida and a 100-bed facility in Anoopshahr. During the year, Max Healthcare added 856 operational beds, expanding its capacity from 3,798 to 4,654 beds.
In Q4 FY25, the Average Revenue Per Occupied Bed (ARPOB) stood at ₹77.1K, marginally higher than ₹76.8K in Q4 FY24 and ₹75.9K in Q3 FY25. Revenue from international patients grew 28% year-on-year and contributed approximately 9% to overall hospital revenue. Digital revenue accounted for nearly 28% of hospital revenue.
The board recommended a final dividend of ₹1.50 per equity share, subject to shareholder approval.
Over the last three years, Max Healthcare has given multibagger returns of more than 200%.
NHPCQ4FY25
Revenue ₹2,347 crores 🔼 25%
PAT ₹920 crores 🔼 52%
FY25
Revenue ₹10,380 crores 🔼 8%
PAT ₹3,412 crores 🔻 15%
NHPC commissioned two major renewable energy assets during the year — the 800 MW Parbati-II Hydro Electric Project and 107.14 MW of the 300 MW Kamisar Solar Power Plant in April 2025, further strengthening its generation portfolio.
NHPC also completed the amalgamation of Lanco Teesta Hydro Power Ltd (LTHPL) with effect from April 1, 2022, and filed the first motion application for the merger of Jalpower Corporation Ltd (JPCL). These moves aim to streamline operations and integrate project execution within the NHPC ecosystem.
The board has recommended a final dividend of ₹0.51 per share for FY25.
Over the last three years, this stock has given multibagger returns of more than 170%.
DIXONQ4FY25
Income ₹10,293 crores 🔼 121%
PAT ₹249 crores 🔼 157%
FY25
Revenue ₹38,860 crores 🔼 120%
PAT ₹843 crores 🔼 125%
Dixon Technologies saw strong expansion across its manufacturing footprint and product categories in FY25, reinforcing its position as a leading contract manufacturer in India. During the year, the company completed the acquisition of a 50.1% stake in Ismartu India Pvt Ltd, strengthening its presence in smartphone manufacturing. It also incorporated new subsidiaries as part of its effort to scale capabilities across electronics, IT hardware, and telecom segments.
In terms of capacity and capability building, Dixon continued expanding its manufacturing infrastructure, automation efforts, and backward integration across categories. It enhanced its portfolio in consumer electronics, mobile phones, lighting, wearables, and home appliances, while also stepping up exports and assembling products for marquee global brands under the “Make in India” umbrella.
The board recommended a final dividend of ₹8 per equity share, subject to shareholder approval.
Over the last three years, Dixon has given multibagger returns of more than 350%.
Note: The stock prices mentioned are as of 2:15 PM.
Disclaimer
Investments in securities market are subject to market risks, read all the related documents carefully before investing. This is for informational purposes and should not be considered as recommendations.
Kindly refer to https://share.market/ for more details.
PhonePe Wealth Broking Private Limited is a member of NSE & BSE with SEBI Regn. No.: INZ000302639, Depository Participant of CDSL Depository with SEBI Regn. No.: IN-DP-696-2022, Research Analyst with SEBI Regn No: INH000013387, BSE RA Enlistment Number: 5887, and Mutual Fund distributor with AMFI Registration No: ARN- 187821. Member ID: BSE- 6756, NSE- 90226.
Registration granted by SEBI, enlistment as Research Analyst, and Certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors
Registered office – 2, Floor 3, Wing A, Block A, Salarpuria Softzone, Service Road, Green Glen Layout, Bellandur, Bengaluru South, Bengaluru, Karnataka – 560103, INDIA.
CIN: U65990KA2021PTC146954.
